Do cardioselective β-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure?

American Journal of Cardiovascular Drugs

Volumn 9, Issue 4, 2009, Pages 231-240

  Subramanian, Usha ^a   Kamalesh, Masoor ^a   Temkit, M'Hamed ^a   Eckert, George J ^a   Sawada, Stephen ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; METOPROLOL; NITRATE; SPIRONOLACTONE;

AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL TIME;

ADRENERGIC BETA-ANTAGONISTS; AGED; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE; HOSPITALS, VETERANS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 70349149848     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/1006180-000000000-00000     Document Type: Article

References (46)

1. Kamalesh M, Nair G. Increasing prevalence of diabetes among patients with congestive heart failure. Int J Cardiol 2005; 104 (1): 77-80
2. Adams Jr KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149 (2): 209-216
3. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005; 46 (6): 1116-1143
4. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004; 9: 243-255
5. Deedwania PC, Giles TD, Klibaner M, et al. MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149 (1): 159-167
6. CIBIS-II Investigators and Committees. The cardiac insufficiency and bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9-13
7. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure. (MERIT-HF). Lancet 1999; 353: 2001-2007
8. Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta blockers in patients with heart failure who have diabetes? Results of the COPERNICUS Study [abstract no. 3551]. Circulation 2001; 104: II-754
9. Bell DS, Lukas MA, Holdbrook FK, et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006; 22: 287-296
10. Subramanian U, Fihn S, Weinberger M, et al. A controlled trial of including symptom data in computer-based care suggestions for managing patients with chronic heart failure. Am J Med 2004; 116: 375-380
11. Subramanian U, Fihn S, Weinberger M, et al. Diagnostic challenges defining chronic heart failure when using echocardiograms. Am J Cardiol 2003; 91 (8): 1015-1017
12. Martin DK. Making the connection: the VA-Regenstrief project. MD Comput 1992; 9: 91-96
13. Fisher SG, Weber L, Goldberg J, et al. Mortality ascertainment in veteran population: alternatives to the National Death Index. Am J Epidemiol 1995; 141: 242-250
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
15. Polanczyk CA, Rohde LE, Philbin EA, et al. A new casemix adjustment index for hospital mortality among patients with congestive heart failure. Med Care 1998; 36: 1489-1499
16. Iezzoni LI, Ash AS, Shwartz M, et al. Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes. Ann Intern Med 1995; 123: 763-770
17. Pine M, Norusis M, Jones B, et al. Predictions of hospital mortality rates: a comparison of data sources. Ann Intern Med 1997; 126: 347-354
18. Tierney WM, Takesue BY, Vargo DL, et al. Using electronic medical records to predict mortality in primary care patients with heart disease: prognostic power and pathophysiologic implications. J Gen Intern Med 1996; 11: 83-91
19. Freedland KE, Carney RM. Psychosocial considerations in elderly patients with heart failure. Clin Geriatr Med 2000; 16: 649-661
20. Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement conference on palliative and supportive care in advanced heart failure. J Cardiac Fail 2004; 10 (3): 200-209
21. Gavazzi A, De Maria R, Parolini M, et al. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 2000; 85: 1114-1118
22. Carney RM, Freedland KE, Miller GE, et al. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002; 53: 897-902
23. Murberg TA, Bru E, Svebak S, et al. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-year follow-up study. Int J Psychiatry Med 1999; 29: 311-326
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619
25. Bouvy ML, Heerdink ER, Leufkens HG, et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003; 89: 605-609
26. Tierney WM, Brunt M, Kesterson J, et al. Quantifying risk of adverse clinical events with one set of vital signs among primary care patients with hypertension. Ann Fam Med 2004; 2: 209-217
27. Ware J. SF-36 Physical and mental health summary scale: a user's manual. Boston (MA): Health Assessment Lab, New England Medical Center, 1994
28. Guyatt G. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993; 22: 185-91A
29. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245-1255
30. D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281
31. Subramanian U, Eckert G, Yeung A, et al. A single health status question has important prognostic value among outpatients with chronic heart failure. J Clin Epidemiol 2007; 60 (8): 803-811
32. Haas SJ, Vos T, Gilbert RE, et al. Are beta blockers as efficacious in patients with diabetes as in patients without diabetes who have chronic heart failure? A meta-analysis of large scale clinical trials. Am Heart J 2003; 146: 848-853
33. Zaca V, Rastogi S, Mishra S, et al. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology 2009; 112: 294-302
34. Nishio Y, Kashiwagi A, Kida Y, et al. Deficiency of cardiac beta-adrenergic receptor in streptozocin-induced diabetic rats. Diabetes 1988; 37: 1181-1187
35. Gotzsche O. The adrenergic beta-receptor adenylate cyclase system in heart and lymphocytes from streptozotocin-diabetic rats: in vivo and in vitro evidence for a desensitized myocardial beta-receptor. Diabetes 1983; 12: 1110-1116
36. Cros GH, Chanez PO, Michel A, et al. Cardiac beta-adrenergic receptors in diabetic rats: alteration of guanyl nucleotide regulation. J Pharmacol 1986; 17: 595-600
37. Lowes BD, Baker ML, Blaxall BC. Gene expression profile of the recovering human heart. Eur Heart J 2007; 28 (5): 522-524
38. Dulin BR, Haas SJ, Abraham WT, et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12 000 patients in large-scale clinical trials. Am J Cardiol 2005; 95: 896-898
39. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993; 4: 61-71A
40. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17 Suppl. B: 8-16
41. Jugdutt BI, Joljart MJ, Khan MI. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation 1996; 94: 94-101
42. Doering CW, Jalil JE, Janicki JS, et al. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 1988; 22: 686-695
43. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen post infarction. J Am Coll Cardiol 2000; 36: 276-281
44. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737
45. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560
46. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. Eval Rev 2005; 29: 530-558